Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Drug

BeiGene’s Tislelizumab Faces FDA Delay Due to Inspection Hurdles

Fineline Cube Jul 15, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced a delay in the U.S. FDA’s decision...

Company Deals Drug

Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development

Fineline Cube Jul 15, 2022

China-based Frontier Biotechnologies Inc. (SHE: 200342) announced a strategic partnership with Asymchem Laboratories (Tianjin) Co.,...

Company Medical Device

Acotec Scientific’s AcoArt Orchid & Dhalia DCB Wins China Approval for AVF PTA

Fineline Cube Jul 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its AcoArt Orchid & Dhalia DCB,...

Company Deals

Orion Holdings to Build Jining Vaccine Plant in China’s Shandong Province

Fineline Cube Jul 14, 2022

South Korea-based conglomerate Orion Holdings Corp. will enter China’s vaccine market by constructing a manufacturing...

Company Drug

Hangzhou DAC Biotech Doses First Patient in DXC007 AML Study

Fineline Cube Jul 14, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing in a...

Company Deals

Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline

Fineline Cube Jul 14, 2022

China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its...

Company Drug

Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection

Fineline Cube Jul 14, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...

Policy / Regulatory

China’s 2021 Healthcare Report Shows Rising Life Expectancy, Increased Medical Spending

Fineline Cube Jul 14, 2022

China’s National Health Commission (NHC) released the “Healthcare Statistical Communique 2021,” revealing increased healthcare spending,...

Company Deals

Sinopharm Biotec and Ganzhou Government Partner on Medical Testing and Biotech R&D

Fineline Cube Jul 14, 2022

Sinopharm China National Biotec Group Co., Ltd (CNBG) announced a strategic partnership with the government...

Company Deals

Basecare Medical and Haier Biomedical Partner on IVF Cryopreservation Tech

Fineline Cube Jul 14, 2022

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) announced a strategic partnership with...

Company Drug

Huadong Medicine’s Biosimilar Victoza (Liraglutide) Accepted for NMPA Review

Fineline Cube Jul 14, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Company R&D

CorrectSequence Therapeutics’ tBE Tech Wins USPTO Patent for Gene Editing

Fineline Cube Jul 14, 2022

Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...

Company Drug

Zai Lab’s Efgartigimod NDA Accepted by NMPA for Myasthenia Gravis

Fineline Cube Jul 14, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the National Medical Products Administration (NMPA)...

Company Deals

Overland ADCT BioPharma Doses First Patient in Zynlonta’s Phase III LOTIS-5 Study for DLBCL

Fineline Cube Jul 14, 2022

Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...

Company Deals

Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery

Fineline Cube Jul 14, 2022

China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...

Company Drug

Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers

Fineline Cube Jul 13, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...

Company Deals

GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development

Fineline Cube Jul 13, 2022

GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...

Company Drug

Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment

Fineline Cube Jul 13, 2022

Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...

Policy / Regulatory

NMPA Reclassifies Glucosamine Sulfate to OTC, Mandates Label Revisions

Fineline Cube Jul 13, 2022

China’s National Medical Products Administration (NMPA) announced that potassium glucosamine sulfate has been reclassified from...

Policy / Regulatory

China’s JPO Launches VBP Round for Orthopedic Spine Consumables

Fineline Cube Jul 13, 2022

China’s Joint Procurement Office (JPO) announced plans on July 11 to conduct a volume-based procurement...

Posts pagination

1 … 693 694 695 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.